Protherics (MM) (PTIL) News

Protherics PLC Announces Research Update
Wednesday August 27, 2:01 am ET

Cheshire, UK--(MARKET WIRE)--Aug 27, 2008 --

Protherics PLC

Start of ProlarixTM phase 2 study in liver cancer

London, UK; Brentwood, TN, US; 27 August 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, today
announces the initiation of a phase 2a proof-of-concept study of
ProlarixTM, a targeted prodrug chemotherapy being developed for the
treatment of primary liver cancer (hepatocellular carcinoma or "HCC").
This follows promising data from a phase 1 study of Prolarix, presented
at the American Society of Clinical Oncology (ASCO) Annual Meeting
in Chicago, USA on 2 June 2008.

HCC is the sixth most common cause of cancer in the world1 and despite
the recent approval of sorafenib (Nexavar®, Onyx/Bayer), a new
chemotherapy which is being adopted as the standard of care for
HCC, life expectancy remains less than 12 months from diagnosis.
Moreover, less than 20% of patients survive beyond one year, and less
than 5% survive beyond five years.

The phase 2a proof-of-concept study is designed to evaluate tumour
response in addition to safety and tolerability of Prolarix in 14
patients with non-resectable HCC who have not been treated
with sorafenib. The study has been initiated at a site in Belgium and
additional study sites in East Asia have been identified for inclusion
in the study. The results of the study are expected in the second half
of 2009.


Andrew Heath, Chief Executive of Protherics commented:"Scientifically
acclaimed, Prolarix offers renewed hope for the many
patients with primary liver cancer for whom there are very few
treatment options. If the results from this study are positive, a
licensing partner will be sought for Asia where the incidence of this
type of cancer is highest."

Press Release Source: Protherics PLC


Protherics PLC - Rule 2.10 Announcement
Thursday August 14, 4:41 am ET


CHESHIRE, UK--(MARKET WIRE)--Aug 14, 2008 --



Protherics PLC

Rule 2.10 Announcement


London, UK; Brentwood, TN, US; 14 August 2008

In accordance with Rule 2.10 of the City Code on Takeovers and Mergers
(the "Code"), Protherics confirms that at the close of business
on 13 August 2008, it has 342,159,034 ordinary shares of 2 pence each
in issue and admitted to trading on the London Stock Exchange under the
UK ISIN code GB0007029209.

The ISIN number above corrects that cited in the Rule 2.4 announcement
issued by the Company on 13 August 2008.


ENDS


For further information please contact:


Protherics +44 (0)20 7246 9950
Andrew Heath, CEO
Rolf Soderstrom, Finance Director
Nick Staples, Director of Corporate Affairs

Jefferies International Ltd.
Ian Crosbie +44 (0)20 7029 8000

Nomura Code Securities Ltd.
Chris Collins +44 (0) 207 776 1200

Financial Dynamics - press enquiries
Ben Atwell +44 (0) 20 7831 3113



Or visit http://www.Protherics.com


Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Code, if any person is, or
becomes, interested" (directly or indirectly) in 1% or more of any
class of "relevant securities" of Protherics, all "dealings" in
any"relevant securities" of that company (including by means of an option
in respect of, or a derivative referenced to, any such "relevant
securities") must be publicly disclosed by no later than 3.30 pm
(London time) on the London business day following the date of the
relevant transaction. This requirement will continue until the date on
which the offer becomes, or is declared, unconditional as to
acceptances, lapses or is otherwise withdrawn or on which the "offer
period" otherwise ends. If two or more persons act together pursuant to
an agreement or understanding, whether formal or informal, to acquire
an "interest" in "relevant securities" of Protherics, they will be
deemed to be a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all "dealings" in"relevant
securities" of Protherics by a potential offeror, or
by Protherics, or by any of their respective "associates", must be
disclosed by no later than 12.00 noon (London time) on the London
business day following the date of the relevant transaction.

A disclosure table, giving details of the companies in whose "relevant
securities""dealings" should be disclosed, and the number of such
securities in issue, can be found on the Takeover Panel's website at

Protherics PLC announces Research Update
Wednesday August 6, 2:20 am ET

CHESHIRE, UK--(MARKET WIRE)--Aug 6, 2008 --

Protherics PLC

DEEP results in pre-eclampsia to be presented at leading conference

London, UK; Brentwood, TN, US; 6 August 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, today announces that data
from the "DEEP" study has been selected as one of the
key presentations at the 16th World Congress of The International
Society for the Study of Hypertension in Pregnancy (ISSHP) in
Washington DC, US 21-25 September 2008.


On 22 April Protherics announced that its placebo-controlled phase
2b Digibind® Efficacy Evaluation in Pre-eclampsia ("DEEP") study in
severe pre-eclampsia met one of its two primary endpoints. An abstract
of the study results prepared by Protherics and other stakeholders in
the programme has been selected by ISSHP for presentation at the
opening plenary session on 22 September 2008. In addition,
two abstracts describing research data supporting the mechanism of
action of Digoxin Immune Fabs (DIFs) in pre-eclampsia have also been
accepted for presentation. Please see the ISSHP's website for more
details: http://www.isshp2008-washington.org/


Dr Garrett K. Lam, lead clinical investigator on the DEEP
study commented, "The opportunity to present the results of the DEEP
study at the ISSHP's World Congress reflects the considerable
scientific and medical interest in this important study
in pre-eclampsia, as this is the first time a drug has shown a clinical
benefit towards improving an end organ function in pre-eclamptic
patients. This study will advance efforts to identify the underlying
cause(s) of this life-threatening condition."


Andrew Heath, CEO commented: "We are delighted that the DEEP study
results will be one of the leading presentations at this prestigious
meeting. Discussions with key stakeholders about how to progress this
important programme continue, and we are encouraged by the interest
shown in the programme to date. We expect to give a further update on
next steps towards the end of the year."


Protherics also announces today that a patent has been granted in
the US covering the use of DIFs, including Digibind® (GlaxoSmithKline)
and DigiFabTM, as a method for controlling pre-eclampsia and eclampsia.


http://biz.yahoo.com/iw/080806/0422406.html



surf's up......crikey

Protherics PLC announces Research Update
Tuesday June 24, 2:00 am ET

Cheshire, UK--(MARKET WIRE)--Jun 24, 2008 --

Protherics PLC

Start of phase 2a clinical study of Angiotensin Therapeutic Vaccine
in hypertension

London, UK; Brentwood, TN, US; 24 June 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, today announces that the
first patient has been enrolled in a phase 2a study of its Angiotensin
Therapeutic Vaccine (ATV) for the treatment of hypertension.


Hypertension is a major risk factor for serious and common
cardiovascular diseases such as heart attacks and strokes and the
global market for anti-hypertensive therapies is estimated to be worth
around USUSD30 billion*. The majority of existing therapies are tablets
which need to be taken on a daily basis, usually for the rest of a
patient's life. However, many patients with high blood pressure fail
to take their medicines as prescribed, and it is estimated that
approximately 70% of patients with hypertension do not have their blood
pressure adequately controlled*. Therefore, a vaccine approach, which
may require only three injections and a booster after six months rather
than daily medication, should improve patient compliance with treatment.


The phase 2a, double-blind, placebo-controlled clinical study in
124 patients with mild to moderate hypertension has been initiated in
the UK. Patients will be given a course of injections over six weeks.
The study will assess the safety and tolerability of the vaccine,
incorporating Protherics' promising novel vaccine adjuvant, CoVaccine
HT(TM). In addition both antibody response and effect on blood
pressure will be assessed. The blood pressure results are expected in
the first half of 2009.


Protherics has shown in a previous phase 2a study that a formulation of
ATV, incorporating the vaccine adjuvant Alhydrogel®, modulated key
hormones involved in regulating blood pressure in hypertensive
patients. A new formulation of ATV has now been developed,
incorporating the CoVaccine HT(TM) adjuvant, which has demonstrated a
much stronger immune response in pre-clinical models.


CoVaccine HT(TM) and ATV are protected by extensive patents and
applications in the US, EU and the rest of the world. The first US
patent on ATV was granted in May 2008.



Andrew Heath, Chief Executive of Protherics, commented:"We are excited
about the prospects for ATV, a potential value driver
for the company. A vaccine approach to the treatment of high blood
pressure promises to address the issue of poor patient compliance with
daily medication and thus reduce the incidence of stroke and heart
attacks. With data expected within a year, this could be a major
outlicensing opportunity."

Protherics PLC announces Holding(s) in Company - 1
Friday June 13, 1:11 pm ET

Cheshire, UK--(MARKET WIRE)--Jun 13, 2008 --

Protherics PLC

Notification of Major Interests in Shares

London, UK; Brentwood, TN, US: 13 June 2008 - Protherics PLC
("Protherics" or the "Company"), the international biopharmaceutical
company focused on critical care and cancer, announces that today, in
accordance with the Transparency Obligations
Directive, a notification of interest in the ordinary share capital of
the Company was received from Invesco Perpetual on behalf of Perpetual
Income and Growth Investment Trust. Details of
the interest notified are as follows:

1. Reason for the notification (please tick the appropriate box or
boxes)

An disposal of voting rights Yes

An acquisition or disposal of financial instruments which may
result in the acquisition of shares already issued to which voting
rights are attached

An event changing the breakdown of voting rights

Other (please specify):

2. Full name of person(s) subject to the Perpetual Income and
notification obligation: Growth Investment
Trust

3. Full name of shareholder(s) (if different from 2.):

4. Date of the transaction (and date on which the 12 June 2008
threshold is crossed or reached if different):

5. Date on which issuer notified: 13 June 2008

6. Threshold(s) that is/are crossed or reached: crossed 4% threshold
into 3%

7. Notified details:



A: Voting rights attached to shares

Class/type of Situation previous Resulting situation after the triggering
shares to the Triggering transaction
transaction
if possible
using the ISIN Number of Number of Number of Number of voting % of voting
CODE Shares Voting shares rights rights
Rights
Direct Indirect Direct
Indirect
14,348,079 14,348,079 13,568,085 13,568,085 3.98%
Ordinary 2P
Shares
(GB0007029209)




B: Financial Instruments

Resulting situation after the triggering transaction

Type of Expiration Exercise/ Number of voting rights that % of
financial date Conversion may be acquired if the voting
instrument Period/ instrument is exercised/ rights
Date converted.




Total (A+B)

Number of voting rights % of voting rights


13,568,085 3.98%



8. Chain of controlled undertakings through which the voting rights and
/or the financial instruments are effectively held, if applicable :

Name of Company/Fund Number of % of issued
Shares share capital


Citibank 13,568,085 3.98%



Proxy Voting:

9. Name of the proxy holder:



10. Number of voting rights proxy holder will cease to hold:



11. Date on which proxy holder will cease to hold voting rights:



12. Additional information:




/ Ends /


For further information please contact:


Protherics

Nick Staples, Director of Corporate Affairs +44 (0) 7919 480510

Julie Vickers, Company Secretary +44 (0)1928 518010


Financial Dynamics - press enquiries

London: Ben Atwell, Lara Mott +44 (0) 20 7831 3113

New York: John Capodanno, Jonathan Birt +1 212 850 5600



Or visit http://www.protherics.com

This information is provided by RNS
The company news service from the London Stock Exchange

END




surf's up......crikey

Protherics PLC announces Notice of Results
Thursday May 15, 2:40 am ET

Cheshire, UK--(MARKET WIRE)--May 15, 2008 -- PROTHERICS PLC

Notification of Preliminary Results

London, 15 May 2008: Protherics PLC ("Protherics"), the biopharmaceutical company focused on critical care and cancer, will be announcing its preliminary results for the year ended 31 March 2008, on Tuesday 3 June 2008.

An analyst meeting will be held at 9.30am at the offices of Financial Dynamics, 26 Southampton Buildings, London, WC2A 1PB.

Enquiries:

Protherics PLC +44 (0) 20 7246 9950

Nick Staples, Corporate Affairs

Financial Dynamics +44 (0) 20 7831 3113

Mo Noonan
Contact:

Source: Protherics PLC

Protherics PLC announces Total Voting Rights
Tuesday April 1, 1:26 pm ET

Cheshire, UK--(MARKET WIRE)--Apr 1, 2008 --

Protherics PLC

Total Voting Rights and Share Capital

London, UK; Brentwood, TN; 1 April 2008 - In conformity with the Transparency Directive, Protherics PLC ("Protherics"), the international biopharmaceutical company focused on critical care and cancer, notifies the market of the following:

Protherics' issued share capital consists of 340,319,609 ordinary shares with a nominal value of 2 pence each, with voting rights. Protherics does not hold any ordinary shares in Treasury. Therefore, the total number of voting rights in Protherics is 340,319,609.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, Protherics under the Financial Services Authority's Disclosure and Transparency Rules.

Cephalon’s New CLL Drug Should Please Patients and Investors(PTIL):

http://seekingalpha.com/article/70443-cephalons-new-cll-drug-should-please-patients-and-investors?source=yahoo

Press Release Source: Protherics PLC

Protherics PLC announces Research Update
Friday January 11, 2:00 am ET

Cheshire, UK--(MARKET WIRE)--Jan 11, 2008 --

Protherics PLC

Protherics and Advancell start Acadra(TM) clinical study
in B-cell chronic lymphocytic leukaemia


London, UK; Brentwood, TN, US; 11 January 2008 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, and its co-development partner, Advancell s.l. ("Advancell"),
today announce that the first patient has now been enrolled in a recently
initiated phase 1/2 clinical study of Acadra(TM) (acadesine) in B-cell chronic
lymphocytic leukaemia (B-CLL).

Most drugs currently used to treat B-CLL also kill T-cells, suppressing the
patient's immune system and increasing the risk of serious infection; a common
cause of death in patients with B-CLL. Acadra(TM) is a potentially selective
treatment for B-CLL which has been shown to cause the death of B-cells whilst
sparing T-cells in blood samples from patients with B-CLL. Acadra(TM) has also
shown the capacity to kill B-CLL cells that are resistant to current therapies,
such as fludarabine. Protherics and Advancell are jointly developing Acadra(TM)
in this indication following a licensing and co-development agreement announced
in December 2006.

The phase 1/2 study will be conducted at sites in Belgium, France and Spain and
will enroll up to 30 B-CLL patients who have relapsed or are refractory to
existing chemotherapy. The open-label study is designed to assess the safety,
tolerability, pharmacokinetics and the effects on Acadra(TM) on B-cell and T-
cell counts. Part I of the study will investigate escalating single doses of
Acadra(TM) following in part II by an assessment of repeated doses. Results from
part I of the study are expected in the second half of 2008 and the final study
results are expected in the first half of 2009.

Luis Ruiz-Avila, Chief Executive Officer of Advancell, commented:

"We are delighted that Acadra has entered its first clinical study in patients
with B-CLL. The current study is designed to demonstrate proof of concept in
terms of the selective targeting of B-cells in patients that are resistant or
refractory to fludarabine."

Andrew Heath, Chief Executive of Protherics, commented:

"Acadra is an exciting new therapy being developed to improve the safety and
tolerability of chemotherapy in B-CLL patients. We expect to get an early
indication of selectivity in this open-label study and we are encouraged by the
strong ex-vivo data generated to date."

http://biz.yahoo.com/iw/080111/0347391.html

Protherics UK Ltd. Chooses TrackWise for Corrective Action and Preventive Action (CAPA) Management

HOLMDEL, N.J., Oct. 24 /PRNewswire/ -- Sparta Systems, Inc. (Sparta), the maker of TrackWise(R), and the market leader in enterprise quality and compliance management software, announced that its TrackWise solution has been chosen by Protherics UK, a leading biopharmaceutical company focused on the development, manufacturing and marketing of specialized products for critical care and cancer, to manage its CAPA and complaint handling processes.

TrackWise provides organizations with a single, consolidated tool for managing corrective and preventive actions originating from any source using a single software platform. TrackWise improves control over the corrective and preventive action process by streamlining and automating workflow, escalating high risk or past due actions, and providing consolidated reporting across various risk areas.

'TrackWise from Sparta Systems greatly enhanced our ability to control and monitor key aspects of our business quality processes. The ability to quickly and accurately map the software to our existing systems has led not only to an excellent business fit, but has made uptake and acceptance of TrackWise within the business a very straightforward exercise,' said Darren Topham, Global IT Manager. 'TrackWise helps us ensure fast approval times and efficient monitoring of the status and effectiveness of all CAPAs.'

'We are pleased to partner with Protherics UK Ltd., with our quality management system that ensures reduced IT administration costs by consolidating redundant systems,' said Yaniv Vardi, Vice President, Operations at Sparta Systems Europe. 'In addition to providing Protherics with a closed- loop CAPA process with electronic workflow and built-in effectiveness checks, TrackWise also provides them with quality trending and management reporting through integrated search tools, reporting functions, and management dashboards.'

About Sparta Systems

Sparta Systems, Inc. is the industry leader for global quality and compliance management systems. Its TrackWise product is a web-based enterprise software application used by quality, manufacturing, regulatory affairs, and business professionals to manage quality, compliance issues, and action items across the enterprise. The company has more than 12 years of experience and an extensive customer base in the life sciences and other highly regulated industries. Sparta Systems offers its customers a complete solution for global quality management needs, including the onsite support required throughout the project lifecycle. More information about Sparta Systems and TrackWise can be found at www.sparta-systems.com.

About Protherics

Protherics (LSE: PTI, Nasdaq: PTIL) is a leading biopharmaceutical company focused on the development, manufacture and marketing of specialized products for critical care and cancer. With headquarters in London, the Company has approximately 260 employees across its operations in the UK, US and Australia. For further information on Protherics or its products please visit www.protherics.com

PR Contacts:
Jon Rabinowitz
Director of Marketing
Sparta Systems, Inc.
Tel: 732-203-0400 x121
jon.rabinowitz@sparta-systems.com

SOURCE Sparta Systems, Inc.

Source: PR Newswire (October 24, 2007 - 5:53 PM EDT)

News by QuoteMedia
www.quotemedia.com

Protherics PLC announces Licensing Agreement

Protherics PLC

Protherics signs ReGel(TM) licensing agreement
with Myungmoon Pharm.

London, UK; Brentwood, TN, US; 25 September 2007 - Protherics PLC ("Protherics"
or the "Company"), the international biopharmaceutical company focused on
critical care and cancer, today announces that it has signed a licensing
agreement with Myungmoon Pharm. Co. Ltd., a Korean pharmaceutical company,
granting it the rights to develop anti-inflammatory products using Protherics'
novel proprietary local, sustained release drug delivery system ReGel(TM).

Protherics will receive a small upfront payment on signing the agreement and
royalties on any net sales in the Republic of Korea. Under the agreement,
Protherics also has an option on agreed terms to the global rights outside of
the Republic of Korea to any products developed under the agreement.

Mr G.H. Lee, President of Myungmoon Pharm. Co. Ltd. commented:

"We are excited to have signed this agreement to use ReGel in the development of
locally administered, sustained release anti-inflammatory products for arthritis
and other potential indications."

Andrew Heath, Chief Executive of Protherics commented:

"Protherics' ReGel is a unique drug delivery system, gained through our
acquisition of MacroMed Inc, which has broad applicability beyond its use in
OncoGel, our proprietary formulation of paclitaxel in phase II development for
cancer. There is encouraging interest from a number of major companies to
develop products utilising ReGel for a range of indications."

Protherics PLC announces Notification of Major Interests in Shares


Protherics PLC

Notification of Major Interests in Shares


London, UK; Brentwood, TN, US: 21 August 2007 - Protherics PLC ("Protherics" or
the "Company"), the international biopharmaceutical company focused on critical
care and cancer, announces that on 20 August 2007, in accordance with the
Transparency Obligations Directive, a notification of interest in the ordinary
share capital of the Company was received from AXA Investment Managers UK
Limited on behalf of AXA S.A. and its Group companies ("AXA"). The notification
follows an increase in the Indirect voting rights of AXA from 10.94% to 11.01%
of total voting rights. Details of their interest are as follows: